April 2009
Volume 50, Issue 13
ARVO Annual Meeting Abstract  |   April 2009
Efficacy of Topical KinostatTM for the Prevention of Cataracts in Diabetic Dogs
Author Affiliations & Notes
  • P. F. Kador
    Pharmaceutical Sciences, College of Pharm, Univ of Nebraska Medical Ctr, Omaha, Nebraska
    Therapeutic Vision, Inc., Omaha, Nebraska
  • I. D. Bras
    Ophthalmology, MedVet Medical Center for Pets, Worthington, Ohio
  • T. R. Webb
    Ophthalmology, MedVet Medical Center for Pets, Worthington, Ohio
  • K. Ketring
    All Animal Eye Clinic, Cincinnati, Ohio
  • M. Wyman
    Therapeutic Vision, Inc., Omaha, Nebraska
    Ophthamology, College of Veterinary Medicine, Columbus, Ohio
  • Footnotes
    Commercial Relationships  P.F. Kador, Therapeutic Vision, E; Therapeutic Vision, P; I.D. Bras, None; T.R. Webb, None; K. Ketring, None; M. Wyman, Therapeutic Vision, E; Therapeutic Vision, P.
  • Footnotes
    Support  NEI SBIR 1R43EY018013-01A1
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 5183. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      P. F. Kador, I. D. Bras, T. R. Webb, K. Ketring, M. Wyman; Efficacy of Topical KinostatTM for the Prevention of Cataracts in Diabetic Dogs. Invest. Ophthalmol. Vis. Sci. 2009;50(13):5183.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Approximately 75% of dogs with diabetes mellitus (DM) develop cataracts within 1 year of the time of diagnosis. Similar cataracts rapidly form dogs fed a diet containing 30% galactose and these are reduced in a dose-dependent manner with the topical aldose reductase inhibitor KinostatTM. The purpose of this study was to investigate whether KinostatTM can similarly prevent or inhibit the progression of cataracts in naturally occurring diabetic dogs.

Methods: : Forty dogs, newly diagnosed with DM and with minimal lens changes were enrolled in a prospective, masked pilot study. Dogs were randomly assigned a coded vial containing either KinostatTM or vehicle (placebo), with the contents of the vial (drug or placebo) masked from the examiner. Twenty-nine dogs received KinostatTM, and 11 dogs received placebo. Owners were instructed to administer the agent OU TID for 1 year, and were instructed to record each time of administration in order to ensure compliance. Complete ophthalmic examinations were performed prior to enrolling in the study, and then at 1, 2, 3, 6, 9, and 12 months after. Digital images were taken after dilation at each time interval. Complete blood chemistries, HbA1C, and Kinostat blood levels were obtained at 1 year.

Results: : Cataract formation and progression was observed in 7/11 (64%) of the dogs receiving placebo with six dogs developing mature cataracts, and one dog developing equatorial vacuoles. Four dogs (36%) in the placebo group did not show evidence of cataract formation at the last follow up; however, the population variance of the placebo group was not significantly different (p<0.13). In contrast, cataract formation in the KinostatTM group was significantly (p<0.02) inhibited with 21/29 (72%) of dogs receiving KinostatTM not showing evidence of cataract development at the last follow up. Eight KinostatTM treated dogs (28%) developed cataracts; (3) incipient anterior cortical cataracts, (1) equatorial vacuoles, (4) mature cataracts. HbA1c values ranged from 8.4-12.3. KinostatTM blood levels were undetectable 1 year after treatment.

Keywords: cataract • diabetes • drug toxicity/drug effects 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.